Top Tech Companies (2,068)
Don't see your company?
Create a company profile
BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. We are passionate about advancing novel therapeutics for patients with rare and serious diseases. Our US headquarters is located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama. With expertise in drug discovery, clinical development, and regulatory affairs, we are advancing clinical programs and generating new compounds from our own discovery engine. We are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. To view our LinkedIn community guidelines, please visit bit.ly/BCRXGuidelines.
Stern Investor Relations is a premier investor relations firm, representing biotechnology companies across all market capitalizations and stages of development, and offering strategic and client-specific advisory services. For more information, email [email protected] or visit our website at www.sternir.com
Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings. Testing for COVID-19 is in high demand. Learn more about our product options. GenBody COVID-19 Ag Test Minimize disruptions with high-volume SARS-CoV-2 antigen testing and results in 15 minutes Learn more: https://talisbio.com/genbody-covid-19-antigen-test/ TALIS ONE™ COVID-19 TEST SYSTEM Rapid point-of-care COVID-19 test that enables highly sensitive SARS-CoV-2 RNA detection from nasal mid-turbinate swabs in less than 30 minutes. With its dual-gene target design, test sensitivity and inclusivity of variants are optimized. Learn more: https://talisbio.com/talis-one-covid-19-test-system/ Our visionary team combines depth of experience with passion to deliver a pioneering solution to infectious disease diagnostics. Infectious disease treatment today is largely guideline-driven: treat patients with similar symptoms the same. Unfortunately, similar symptoms can often have very different causes. Our tests will enable caregivers to know within minutes, the cause of illness, as well as which medications will be effective for their patient, empowering them to provide individualized care rather than broad, guideline-dictated treatments. From the doctor’s office to the hospital bedside to remote care settings, we are re-defining the treatment of infectious diseases.
We are Voyager Therapeutics, a pre-clinical stage biotech compelled by curiosity and powered by persistence. Voyagers are bold innovators who are energized in unlocking the full potential of AAV gene therapy employing our TRACER™ capsid discovery platform. Our resolve is to advance the field of AAV gene therapy, and through our innovative capsids, we are extending the reach and impact of our technology to help more patients in need. Recognizing that we can expand on the experience, innovation, and outcomes that propel our efforts by working together, we actively seek diverse views. If you’re someone who wants to make discoveries that change the landscape of medicine for patients, we want you on our team!
Our team of scientists and engineers are working to evolve the water we drink to improve health from the inside out. The patented Weo biotechnology uses a unique form of electrolysis to amplify the health benefits in water, and is easily installed at home or used on-the-go–making augmented water available to everyone.
Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.
What is exciting about the area we work in Epigenomics is the systematic analysis of the global state of gene expression not attributable to mutational changes across the entire genome. Epigenetic mechanisms are affected by external factors including development in utero and in childhood, environmental chemicals, drugs and pharmaceuticals, aging, and diet. Changes to the epigenetic landscape can have a profound impact on health and disease. Precise mapping and measurement of the epigenetic landscape offers the promise of predictive biomarkers of disease development, even before changes in gene expression have taken place. Epigenomics is the “OME” connecting Genomics to Transcriptomics and Proteomics allowing a Multiomics approach to disease research which will result in a higher yield of data that can be aggregated and analyzed to become actionable information. What does Active Motif offer Epigenetic methods and approaches require the use of high-quality antibodies and enzymes that have undergone strict validation criteria. This allows the development of robust assays for use in mechanistic studies, translational medicine, drug discovery and diagnostics. Active Motif’s Product Development Program takes emerging novel techniques, and develops them into innovative products that allow researchers to perform the assays in their own labs as well as feeding into their end to end services pipeline. Active Motif is building a platform based on their patented transposase based technologies to simplify the interrogation of chromatin, the dynamics of histone modifications, chromatin remodeling, DNA methylation, transcription factor binding, as well as short and long range gene regulation by non-coding regulatory regions. Our bioinformatics platform can take the data generated by these techniques and provide powerful insights into the epigenetic changes occurring in disease or in response to drugs.
Hyperion Biotechnology, Inc. is a woman-owned, service-disabled veteran-owned small business headquartered in San Antonio, TX. As a biomedical and clinical research company, we deliver scientific and technology driven solutions. By growing our business to support a wide range of services, we are a reliable source for support services for our U.S. Department of Defense, federal government and other customers. Hyperion conducts scientific Research and Development in-house in our laboratories located in San Antonio, TX. Our scientists are discovering novel biomarkers to assess human performance outcomes such as physical and cognitive fatigue. Hyperion’s salivary Fatigue Biomarker discoveries enable objective measurement of fatigue. We continue to grow our laboratory services with CLIA certification for clinical reference testing services specializing in toxicology. Hyperion also offers services for environmental microbiology water testing for Legionella. Hyperion holds both CDC ELITE and EMLAP certifications and provides Legionella testing expertise for customers across the United States. CAREERS Hyperion Biotechnology uses a talent acquisition program that seeks talented and innovative scientists, clinical researchers, environmental technicians, support personnel and others to join our team. We staff positions located throughout the United States and support programs in need of experienced PhD level scientists to program managers and administrative and clerical roles. Hyperion is an equal-opportunity employer and offers employees a supportive corporate environment with desirable benefits. We are committed to our employees’ success so they can be committed to our customers’ success. To view and apply for current job openings: http://hyperionbiotechnology.applicantpro.com/jobs/
Rewriting the next 100 years of farming
As of September 2014, G-Biosciences management system governing the manufacture of our products is ISO9001:2008 certified. For more details on G-Biosciences biotechnology and life science research products click the products tab. Geno Technology, Inc. was founded in 1994 with a vision to simplify life science research. Our primary goal was to target the key techniques of protein research and find affordable methods to simplify and improve on these techniques. Over the years Geno Technology, Inc. has branched out into other areas of research, but our primary target still remains with proteins and our primary goal “simplify and improve on these techniques” still holds true. This message was reinforced in 2010 with the evolution of “The Protein Man”, our iconic mascot and the G-Biosciences brand. G-Biosciences’ team examined every aspect of particular experimental techniques, ranging from protein extraction to protein purification and detection, to identify key areas that we could target for improvement. As a result of this we now manufacture everything from simple buffers at convenient concentrations and sizes to custom manufactured devices, such as Tube-O-Dialyzer, that enhance and simplify key techniques. Our key areas we focused on included, but not limited to, protein assays, sample preparation, electrophoresis, Western blotting, mass spectrometry, assay development, antibody production and protein purification. G-Biosciences now offers thousands of products for the protein and life science research market, all designed with the hope of make a researcher’s lab time simpler and more affordable. Geno Biosciences Pvt. Ltd. is a division of Geno Technology, Inc. based in New Dehli, India. G-Biosciences, India is engaged in the distribution of the products manufactured by the parent company. Most recently supplementing G-Biosciences products with other leading manufacturers products to enhance the G-Biosciences inventory.
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.
Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease (ESLD). Ocelot Bio plans to initiate a Phase 2 clinical trial of OCE-205 in the first half of 2022 in HRS-AKI, for which there has been no therapeutic drug innovation in over two decades. The company was founded by leading experts in peptide therapeutic development and is backed by a strong syndicate of investors including Venrock Ventures, RA Capital Management and Vivo Capital. For more information, visit www.ocelotbio.com.
Phanes Therapeutics, Inc. is a biotech company focused on innovative drug discovery and early development in immuno-oncology and eye disease. Our mission is to become a major source of innovation in the biopharma industry. The way we focus on science, the disruptive technologies we develop, and the revolutionary approaches we bring help open up new possibilities in drug discovery. At Phanes, we bring innovation that illuminates the path to cure. Cancer cells cunningly evade the immune system using many different mechanisms. We believe that only when the full potential of the human immune system is unleashed, tumors can be effectively treated or even cured. One of our therapeutic approaches is to boost both the innate and adaptive immunity with monoclonal antibodies and bispecific antibodies. We are also interrogating non-immune pathways that may play key roles in the tumor microenvironment for their potential in developing novel therapeutics. In addition to a strong pipeline, Phanes has developed disruptive technologies that enable drug discovery. Phanes' three novel technology platforms are designed to build native IgG-like bispecific antibodies that enhance drug-like properties. The company has three technology platforms: PACbody™ (for building native IgG-like bispecific antibodies), ATACCbody™ (for building bispecific antibodies with modulated activities) and SPECpair™ (for building bispecific antibodies with enhanced manufacturability). For more information, please visit www.phanesthera.com
Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.
CorDx a multi-national biotech organization focused on pushing the limits of innovation and supply in global health. With over 2,100 employees across the world, serving millions of users in over 100 countries, CorDx delivers rapid testing and point-of-care medical device solutions used in the detection of infectious disease such as COVID-19, pregnancy, drugs of abuse, biomarkers, and more. CorDx is at the cutting edge of technology, artificial intelligence, and data science with the goal of delivering diagnostic solutions to some of the most critical questions in healthcare. #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Bayou City Hemp Company hemp processing and extraction company that utilizes the all-natural process of supercritical CO2 extraction to create CBD and other cannabinoid oils, distillates and isolates. Bayou City Hemp Company focuses on integrity, innovation and education as it partners with key stakeholders to create high quality, clean CBD for end users across many industries. • One of Texas’s Original Hemp Processing & Extraction Companies • Processing Solution and Partner for Texas Farmers • High-Quality CO2 Extraction Lab run by Experienced Professionals • Distribution Sales Network for Oil, Distillate and Isolate Products
Quality Biological (QBI) provides quality solutions for life science research and bioproduction applications. We specialize in producing custom and standard cell culture and molecular biology reagents, buffers, and liquid solutions and providing supporting services. At QBI, we help our clients achieve their application goals faster. We do this by being flexible and nimble, providing a level of personalized service our clients rely on. QBI is home to a fully-equipped, ISO 9001:2015 certified manufacturing facility. At the base of every product is water that exceeds industry specifications. This enables us to provide you with solutions of superior quality and value. We have your solution...whether you need a few liters of medium, buffer or a custom solution for research, dozens of liters of one single lot for process and method validation, or hundreds of liters for commercialization. We work with you to address your specific needs and requirements. Contact us today to discuss your specific media and buffer needs.
